References
- NHLBI/WHO Workshop. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease, Global Initiative for Chronic Obstructive Lung Disease. National Heart, Lung and Blood Institute, Bethesda 2001; 1–100, (updated 2003)
- American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med 1995; 152(5: Pt. 2)S77–S120, [CSA]
- Sears M R. Adverse effects of beta‐agonists. J Allergy Clin Immunol 2002; 110(suppl 6)S322–S328, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Barnes P J, Pedersen S, Busse W W. Efficacy and safety of inhaled corticosteroids, new developments. Am J Respir Crit Care Med 1998; 157(3 Pt. 2)S1–S53, [PUBMED], [INFOTRIEVE], [CSA]
- Brown J E, Taylor P. Muscarinic receptor agonists and antagonists. Goodman & Gilman's The Pharmacological Basis of Therapeutics10th ed., A G Gilman, J G Hardman, L E Limbird. McGraw‐Hill Book Co., New York, NY 2001; 162–168
- Browne K F, Zipes D P, Heger J J, Prystowsky E N. The influence of the autonomic nervous system on the Q‐T interval in man. Am J Cardiol 1982; 50: 1099–1103, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Brodde O E, Michel M C. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 1999; 51: 651–690, [PUBMED], [INFOTRIEVE]
- Disse B. Novel Perspectives in Anticholinergic Therapy. Muscarinic Receptors in Airways Diseases, J Zaagsma, H Meurs, A F Roffel. Birkhaeuser, Basel 2001; 221–258
- Mann K V, Leon A L, Tietze K J. Use of ipratropium bromide in obstructive lung disease. Clin Pharm 1988; 7(9)670–680, [PUBMED], [INFOTRIEVE]
- Anthonisen N R, Connett J E, Enright P L, Manfreda J. Hospitalizations and mortality in the lung health study. Am J Resp Crit Care Med 2002; 166(3)333–339, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Anthonisen N R, Connett J E, Kiley J P, Altose M D, Bailey W C, Buist A S, Conway W A, Enright P L, Kanner R E, O'Hara P, Owens G R, Scanlon P D, Tashkin D P, Wise R A. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1, the lung health study. JAMA 1994; 272(19)1497–1505, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Lanes S, Golisch W, Mikl J. Ipratropium and lung health study. Am J Resp Crit Care Med 2003; 167(5)801, [PUBMED], [INFOTRIEVE], [CSA]
- Disse B, Speck G A, Rominger K L, Witek T J, Hammer R. Tiotropium (Spiriva™): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 1999; 64(6–7)457–464, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Chodosh S, Flanders J S, Kesten S, Serby C W, Hochrainer D, Witek T J. Effective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity. J Aerosol Med 2001; 14(3)309–315, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Casaburi R, Mahler D A, Jones P W, Wanner A, San Pedro G, ZuWallack R L, Menjoge S S, Serby C W, Witek T. A long‐term evaluation of once‐daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Resp J 2002; 19(2)217–224, [CROSSREF]
- Vincken W, Van Noord J A, Greefhorst A P, Bantje T A, Kesten S, Korducki L, Cornelissen P J. Improved health outcomes in patients with COPD during one year's treatment with tiotropium. Eur Resp J 2002; 19(2)209–216, [CROSSREF]
- Donohue J F, van Noord J A, Bateman E D, Langley S J, Lee A, Witek T J, Kesten S, Towse L. A 6‐month, placebo‐controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122(1)47–55, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58(5)399–404, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Calverley P MA, Lee A, Towse L, van Noord, Witek T J, Kesten S. The effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax 2003; 58(10)855–860, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Bazett H. An analysis of the time‐relation of electrocardiograms. Heart 1920; 7: 353–370
- Fridericia L S. Die systolendauer im elektrokardiogramm bei normalen menschen und bei herzkranken. Acta Med Scand 1920; 53: 469–486
- Littner M R, Ilowite J S, Tashkin D P, Friedman M, Serby C W, Menjoge S S, Witek T J. Long‐acting bronchodilation with once‐daily dosing of tiotropium (Spiriva™) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161(4 Pt. 1)1136–1142, [PUBMED], [INFOTRIEVE], [CSA]
- Casale T B, Nelson H S, Stricker W E, Raff H, Newman K B. Suppression of hypothalamic‐pituitary‐adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients. Ann Allergy Asthma Immunol 2001; 87(5)379–385, [PUBMED], [INFOTRIEVE], [CSA]
- Clark D J, Lipworth B J. Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients. Thorax 1997; 52(1)55–58, [PUBMED], [INFOTRIEVE]
- Crane J, Burgess C, Beasley R. Cardiovascular and hypokalaemic effects of inhaled salbutamol, fenoterol, and isoprenaline. Thorax 1989; 44(2)136–140, [PUBMED], [INFOTRIEVE]
- Flatt A, Crane J, Purdie G, Kwong T, Beasley R, Burgess C. The cardiovascular effects of beta adrenergic agonist drugs administered by nebulization. Postgrad Med J 1990; 66(772)98–101, [PUBMED], [INFOTRIEVE]
- Kung M, Croley S W, Phillips B A. Systemic cardiovascular and metabolic effects associated with the inhalation of an increased dose of albuterol, influence of mouth rinsing and gargling. Chest 1987; 91(3)382–387, [PUBMED], [INFOTRIEVE]
- Sin D D, Man P. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases?. Circulation 2003; 107(11)1514–1519, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Cazzola M, Imperatore F, Salzillo A, Di Perna F, Calderaro F, Imperatore A, Matera M G. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest 1998; 114(2)411–415, [PUBMED], [INFOTRIEVE]
- Tsukino M, Nishimura K, Ikeda A, Hajiro T, Koyama H, Izumi T. Effects of theophylline and ipratropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. Thorax 1998; 53(4)269–273, [PUBMED], [INFOTRIEVE]
- Seider N, Abinader E G, Oliven A. Cardiac arrhythmias after inhaled bronchodilators in patients with COPD and ischemic heart disease. Chest 1993; 104(4)1070–1074, [PUBMED], [INFOTRIEVE]
- Mahler D A, Donohue J F, Barbee R A, Goldman M D, Gross N J, Wisniewski M E, Yancy S W, Zakes B A, Rickard K A, Anderson W H. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115(4)957–965, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Rennard S I, Anderson W, ZuWallack R, Broughton J, Bailey W, Friedman M, Wisniewski M, Rickard K. Use of long‐acting inhaled β2‐adrenergic agonist, slameterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163(5)1087–1092, [PUBMED], [INFOTRIEVE], [CSA]
- Kindman L A, Vagelos R H, Willson K, Prikazky L, Fowler M. Abnormalities of pulmonary function in patients with congestive heart failure, and reversal with ipratropium bromide. Am J Cardiol 1994; 73(4)258–262, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Rolla G, Bucca C, Brussino L, Gallo W, Malara D. Bronchodilating effect of ipratropium bromide in heart failure. Eur Respir J 1993; 6(10)1492–1495, [PUBMED], [INFOTRIEVE]
- Uren N G, Davies S W, Jordan S L, Lipkin D P. Inhaled bronchodilators increase maximum oxygen consumption in chronic left ventricular failure. Eur Heart J 1993; 14(6)744–750, [PUBMED], [INFOTRIEVE]